Prevalence [P] of molecular biomarkers [MB] expression [exp] in patients [pts] with metastatic adenocarcinoma lung [MAC]: Illinois CancerCare [ILCC] analysis.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21004-e21004
Author(s):  
Nikhil Kumar ◽  
Patrick Leigh Gomez ◽  
Jamie Harper
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Egfr Mutation ◽  
Growth Factor Receptor ◽  
Metastatic Adenocarcinoma ◽  
Programmed Death Ligand 1 ◽  
Anaplastic Lymphoma ◽  
Programmed Death ◽  
Epidermal Growth ◽  
Former Smokers ◽  
Us Midwest

e21004 Background: Treatment of MAC is guided by MB. These include Programmed Death Ligand 1 (PDL1), Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK) & ROS1. There is little information available on P of MB in US Midwestern population, a largely homogenous Caucasian group. We examined the expression (exp) of the MB in pts with MAC who presented at ILCC in 2018, one of the largest practices in US Midwest. Methods: We conducted a retrospective analysis of all MAC pts who presented at ILCC in 2018. We analyzed the exp of PDL1, EGFR, ALK, and ROS1 in these pts. PDL1 status was defined as high if PDL1 was ≥50%, low if 1- < 50% and -ve if 0- < 1%. High and low groups [all pts with > 1%] were designated +ve. Results: In 2018 there were 125 pts seen at ILCC with MAC. As of 6/2019, 57/125 [46%] pts were alive. Pts: median age 69 yrs [45-89], median PS 1 [0-3], males 62%, current/former smokers 90%, Caucasians 95%. PDL1 results were available in 104/125 pts [83%], EGFR in 95 (76%), ALK in 97 (78%), and ROS1 in 95 (76%). Previously reported papers have described PDL1+ to be as high as 58% in MAC. However, in our study only 53/104 (51%) pts were PDL1+. Though, 26/104 (25%) did have high PDL1 exp [consistent with other reports]. 27/104 (26%) had low PDL1 exp and 51/104 (49%) pts were PDL1-ve. EGFR mutation [M] was found in 11/95 (12%), ALK M was found in 5/97 (5%) pts & ROS1 M was found in 2/95 (2%), the results of these three mutations are consistent with other groups. Conclusions: Our results indicate that exp of PDL1+ pts at ILCC is lower than reported by others, yet the proportion of those with ≥50% PDL1 in our group is similar to others. Exp of EGFR, ALK, and ROS1 in our pts is similar to other studies.[Table: see text]

Lysosome Targeting Chimeras (LYTACs) for the Degradation of Secreted and Membrane Proteins

2019 ◽  
Author(s):  
Steven Banik ◽  
Kayvon Pedram ◽  
Simon Wisnovsky ◽  
Nicholas Riley ◽  
Carolyn Bertozzi
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Membrane Proteins ◽  
Growth Factor Receptor ◽  
Basic Research ◽  
Biochemical Pathway ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
A Cell ◽  
Epidermal Growth ◽  
Powerful Strategy

<p>Targeted protein degradation is a powerful strategy to address the canonically undruggable proteome. However, current technologies are limited to targets with cytosolically-accessible and ligandable domains. Here, we designed and synthesized conjugates capable of binding both a cell surface lysosome targeting receptor and the extracellular domain of a target protein. These lysosome targeting chimeras (LYTACs) consist of an antibody fused to agonist glycopeptide ligands for the cation-independent mannose-6-phosphate receptor (CI-M6PR). LYTACs enabled a CRISPRi knockdown screen revealing the biochemical pathway for CI-M6PR-mediated cargo internalization. We demonstrated that LYTACs mediate efficient degradation of Apolipoprotein-E4, epidermal growth factor receptor (EGFR), CD71, and programmed death-ligand 1 (PD-L1). LYTACs represent a modular strategy for directing secreted and membrane proteins for degradation in the context of both basic research and therapy. <b></b></p>

scholarly journals Frequency of EGFR Mutation and EML4-ALK fusion gene in Arab Patients with Adenocarcinoma of the Lung

2015 ◽  
Vol 6 (2) ◽  
pp. 19-23
Author(s):  
Hanan Ezzat Shafik ◽  
Mohamed Ashour
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Egfr Mutation ◽  
Fusion Gene ◽  
Receptor Gene ◽  
Growth Factor Receptor ◽  
Egfr Mutations ◽  
Anaplastic Lymphoma ◽  
Epidermal Growth

Abstract Introduction: Improvement in the clinical outcome of lung cancer is likely to be achieved by identification of the molecular events that underlie its pathogenesis. The frequency of epidermal growth factor receptor (EGFR) mutations is ethnicity-dependent, with a higher proportion in Asian populations than in whites, while the incidence of EML4-ALK (echinoderm microtubule-associated-protein like 4-anaplastic lymphoma kinase) fusion gene ranged from 1.6% to 16.4% in patients with NSCLC and these individuals were distinct from those harbouring mutations in the epidermal growth factor receptor gene. This study was conducted to determine the frequency of EGFR mutation and EML4-ALK fusion gene in our population and to determine the effect of different clinicopathological features on the expression of those mutations in patients with lung adenocarcinoma. Results: EGFR mutations were detected in approximately 33% of our patients in this series; the most frequently detected mutation was exon 19 deletion. EML4-ALK fusion gene was detected in 7.3% of patients. Conclusion: Our population exhibited the incidence of EGFR mutation approximately similar to that reported in East Asia and Japanese patients, higher than that recorded in USA, and Australia. However, more studies with larger patients’ numbers are needed to verify this finding.

EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer

Nanoscale ◽  
2018 ◽  
Vol 10 (35) ◽  
pp. 16738-16749 ◽  
Author(s):  
Yuan Li ◽  
Yang Du ◽  
Xiaolong Liang ◽  
Ting Sun ◽  
Huadan Xue ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor Receptor ◽  
Colorectal Cancers ◽  
Checkpoint Inhibition ◽  
Immune Checkpoint Inhibition ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Epidermal Growth ◽  
Major Target

The epidermal growth factor receptor (EGFR) is a major target for the treatment of colorectal cancers (CRCs), and programmed death ligand-1 (PD-L1) is an attractive target for CRC immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document